Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the announcement of its 2016 financial reports, which comprised its projections made for 2017. Investors seemed to have focused only on the HCV sales’ revenues while ignoring the sales’ revenues of Gilead’s HIV franchise and other products, which outperformed?

Investors ignored assessing the firm’s pipeline investigational products’ values especially those that might be approved as early as this year and next year, those that are waiting for approvals in many countries around the world after having been approved in the U . . .